|
|
Article: Bentley Pharmaceuticals, Inc. Signs a Licensing Agreement with Biocon Limited to Develop and Market Bentley's Intranasal Insulin Spray in 85 Countries; Announces the Signing of a Commercial Supply Agreement for Insulin API.
- Article from:
- Business Wire
- Article date:
- November 14, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EXETER, N.H. -- -Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that it has signed a product licensing agreement with Biocon Limited for Bentley's intranasal spray formulation for administering insulin. The license agreement covers 85 countries granting Biocon exclusive as well as co-exclusive rights to develop and market Bentley's formulation throughout Asia, Africa, and the Middle East.
Bentley also announced that it has entered into a long term supply agreement with Biocon, which will provide Bentley, and its licensees, ...
Related newspaper, magazine, and journal articles:
|
|
Article: BIOCON LIMITED Consensus Recommendation: HOLD.
TFN/Nelson's Research Reports;
January 23, 2009 ;
297 words
...Jan 23, 2009 (Nelson's Broker Summaries via COMTEX) -- Company: BIOCON LIMITED Consensus Recommendation: HOLD (Strong Buy: 5, Buy: 1, Hold: 3, Underperform: 6, Sell: 1) Quarter Consensus Estimate ...
|
|